Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Monajemi, Mahdis ^a   Woodworth, Claire F ^a   Zipperlen, Katrin ^a   Gallant, Maureen ^a   Grant, Michael D ^a   Larijani, Mani ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; NEF PROTEIN; POL PROTEIN; APOBEC3F PROTEIN, HUMAN; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA; HLA ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE EVASION; NONHUMAN; T LYMPHOCYTE ACTIVATION; VIRUS GENOME; VIRUS MUTATION; WILD TYPE; BIOLOGY; GENETIC VARIABILITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; METABOLISM; MUTATION; VIROLOGY;

CD8-POSITIVE T-LYMPHOCYTES; COMPUTATIONAL BIOLOGY; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA; EPITOPES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; GENOME, VIRAL; HIV-1; HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; MUTATION;

EID: 84899570504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093428     Document Type: Article

References (78)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
2. Harris RS, Petersen-Mahrt SK, Neuberger MS (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 10: 1247-1253. (Pubitemid 35453840)
3. Wedekind JE, Dance GS, Sowden MP, Smith HC (2003) Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 19: 207-216. (Pubitemid 36398423)
4. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 14: 1392-1396. (Pubitemid 39081643)
5. Liddament MT, Brown WL, Schumacher AJ, Harris RS (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14: 1385-1391. (Pubitemid 39081642)
6. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, et al. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435: 108-114. (Pubitemid 40655917)
7. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM (2006) Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 203: 41-46.
8. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, et al. (2007) Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110: 393-400. (Pubitemid 47026861)
9. Pido-Lopez J, Whittall T, Wang Y, Bergmeier LA, Babaahmady K, et al. (2007) Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J Immunol 178: 1671-1679. (Pubitemid 46154639)
10. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC (2007) Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 282: 3539-3546. (Pubitemid 47084447)
11. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474-9485.
12. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, et al. (2006) APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med 203: 2887-2893. (Pubitemid 46026166)
13. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-442. (Pubitemid 38568947)
14. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300: 1112. (Pubitemid 36583087)
15. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103. (Pubitemid 36834849)
16. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98. (Pubitemid 36834848)
17. Klarmann GJ, Chen X, North TW, Preston BD (2003) Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J Biol Chem 278: 7902-7909. (Pubitemid 36800526)
18. Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587-2595. (Pubitemid 47076764)
19. Monajemi M, Woodworth CF, Benkaroun J, Grant M, Larijani M (2012) Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology 9: 35.
20. Belanger K, Savoie M, Rosales Gerpe MC, Couture JF, Langlois MA (2013) Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res 41: 7438-7452.
21. Yu XF (2006) Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr Opin HIV AIDS 1: 187-193.
22. Santa-Marta M, Aires da Silva F, Fonseca AM, Rato S, Goncalves J (2007) HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. Mol Immunol 44: 583-590.
23. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404-1407. (Pubitemid 37466190)
24. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, et al. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 279: 7792-7798. (Pubitemid 38294663)
25. Chiu YL, Greene WC (2009) APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci 364: 689-703.
26. Wichroski MJ, Robb GB, Rana TM (2006) Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2: e41.
27. Chiu YL (2011) Biochemical fractionation and purification of high-molecular-mass APOBEC3G complexes. Methods Mol Biol 718: 185-206.
28. Gallois-Montbrun S, Kramer B, Swanson CM, Byers H, Lynham S, et al. (2007) Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol 81: 2165-2178.
29. Russell RA, Moore MD, Hu WS, Pathak VK (2009) APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 6: 16.
30. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68: 4650-4655. (Pubitemid 24183063)
31. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68: 6103-6110. (Pubitemid 24258634)
32. Perez CL, Larsen MV, Gustafsson R, Norstrom MM, Atlas A, et al. (2008) Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol 180: 5092-5100.
33. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, et al. (2000) Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 96: 3094-3101.
34. Harrer T, Harrer E, Kalams SA, Elbeik T, Staprans SI, et al. (1996) Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 12: 585-592. (Pubitemid 26120291)
35. Almeida CA, Bronke C, Roberts SG, McKinnon E, Keane NM, et al. (2011) Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol 187: 2502-2513.
36. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289. (Pubitemid 38667619)
37. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, et al. (2005) Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 201: 891-902. (Pubitemid 40524459)
38. Geels MJ, Cornelissen M, Schuitemaker H, Anderson K, Kwa D, et al. (2003) Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol 77: 12430-12440. (Pubitemid 37430640)
39. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3: 205-211. (Pubitemid 27064706)
40. Barouch DH, Letvin NL (2002) Viral evolution and challenges in the development of HIV vaccines. Vaccine 20 Suppl 4: A66-68. (Pubitemid 35449408)
41. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
42. Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, et al. (2010) The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med 207: 39-49.
43. Alizon M, Wain-Hobson S, Montagnier L, Sonigo P (1986) Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell 46: 63-74. (Pubitemid 16027826)
44. Mason RD, Bowmer MI, Howley CM, Gallant M, Myers JC, et al. (2004) Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes. J Immunol 172: 7212-7219. (Pubitemid 38669167)
45. Gladney KH, Pohling J, Hollett NA, Zipperlen K, Gallant ME, et al. (2012) Heteroclitic peptides enhance human immunodeficiency virus-specific CD8(+) T cell responses. Vaccine 30: 6997-7004.
46. Pohling J, Zipperlen K, Hollett NA, Gallant ME, Grant MD (2010) Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy. BMC Infect Dis 10: 129.
47. Brennan CA, Ibarrondo FJ, Sugar CA, Hausner MA, Shih R, et al. (2012) Early HLA-B*57-Restricted CD8+ T Lymphocyte Responses Predict HIV-1 Disease Progression. J Virol.
48. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, et al. (2001) Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62: 1009-1030. (Pubitemid 32835065)
49. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, et al. (2006) HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8 (+) T Cell Response against HIV-1. PLoS Med 3: e403.
50. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, et al. (2001) Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 98: 5140-5145. (Pubitemid 32397096)
51. Rohowsky-Kochan C, Skurnick J, Molinaro D, Louria D (1998) HLA antigens associated with susceptibility/resistance to HIV-1 infection. Hum Immunol 59: 802-815. (Pubitemid 28512548)
52. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, et al. (2010) Host determinants of HIV-1 control in African Americans. J Infect Dis 201: 1141-1149.
53. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97: 2709-2714. (Pubitemid 30159236)
54. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, et al. (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41: 1053-1056. (Pubitemid 41368233)
55. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944-947. (Pubitemid 47301321)
56. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, et al. (2009) Common genetic variation and the control of HIV-1 in humans. PLoS Genet 5: e1000791.
57. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, et al. (2008) HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 82: 5398-5407.
58. Poropatich K, Sullivan DJ Jr (2011) Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol 92: 247-268.
59. Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212. (Pubitemid 30099525)
60. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, et al. (2009) HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 4: e6687.
61. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, et al. (2002) Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76: 10155-10168.
62. Karlsson AC, Iversen AK, Chapman JM, de Oliviera T, Spotts G, et al. (2007) Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One 2: e225.
63. Bishop KN, Holmes RK, Malim MH (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80: 8450-8458. (Pubitemid 44384857)
64. Wang X, Dolan PT, Dang Y, Zheng YH (2007) Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem 282: 1585-1594. (Pubitemid 47076698)
65. Betts MR, Krowka JF, Kepler TB, Davidian M, Christopherson C, et al. (1999) Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS research and human retroviruses 15: 1219-1228. (Pubitemid 29411807)
66. Huang XL, Fan Z, Kalinyak C, Mellors JW, Rinaldo CR Jr (2000) CD8+ T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects. Clinical and diagnostic laboratory immunology 7: 279-287. (Pubitemid 30132124)
67. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, et al. (2001) Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 193: 169-180. (Pubitemid 32524449)
68. Letvin NL, Walker BD (2001) HIV versus the immune system: another apparent victory for the virus. Journal of Clinical Investigation 107: 273-275. (Pubitemid 32157959)
69. Smith HC (2011) APOBEC3G: a double agent in defense. Trends Biochem Sci 36: 239-244.
70. Sadler HA, Stenglein MD, Harris RS, Mansky LM (2010) APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 84: 7396-7404.
71. Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. Science 242: 1171-1173. (Pubitemid 19007043)
72. Ji J, Loeb LA (1994) Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene. Virology 199: 323-330. (Pubitemid 24168970)
73. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087-5094.
74. Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242: 1168-1171. (Pubitemid 19007042)
75. Yamanaka R, Termini J (2007) Nucleotide sequence context influences HIV replication fidelity by modulating reverse transcriptase binding and product release. Biosci Trends 1: 52-61.
76. Chelico L, Pham P, Calabrese P, Goodman MF (2006) APOBEC3G DNA deaminase acts processively 3′-<5′ on single-stranded DNA. Nat Struct Mol Biol 13: 392-399. (Pubitemid 43881578)
77. Fourati S, Malet I, Binka M, Boukobza S, Wirden M, et al. (2010) Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. Aids 24: 2313-2321.
78. Yebra G, Holguin A (2011) Mutation Vif-22H, which allows HIV-1 to use the APOBEC3G hypermutation to develop resistance, could appear more quickly in certain non-B variants. J Antimicrob Chemother 66: 941-942.